Oxeltis is a medicinal chemistry services company founded in 2010 by former researchers at Idenix Pharmaceuticals (Ex MSD-company) in Montpellier – France.
The company has a small-scale custom synthesis business, as well as hit and lead optimization services, in various areas such as of antivirals, antibiotics and anticancer compounds.
The Oxeltis team comprises experienced medicinal chemists (65% with PhDs) in 800 m² research labs, with expertise in particular areas of multi-step complex organic synthesis: heterocycles, macrocycles, nucleos(t)ides/phosphoramidites, modified sugars and oligosaccharides… and services of synthesis of E3 ligase ligand-linker conjugates for PROTAC programs.
The team focuses on speed, quality and confidentiality in the services and collaborative ventures that it develops.
Oxeltis works with European, Japanese and North American start-up and big pharma companies as well as research institutions.